This phase 2 trial tests whether a radioactive tracer called 64Cu-DOTA-AE105 can accurately show the aggressiveness of prostate cancer on a PET scan. About 168 men with low- to intermediate-risk prostate cancer will receive the tracer and undergo imaging. The goal is to see if th…
Phase: PHASE2 • Sponsor: Curasight • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC